Overview

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients

Status:
Recruiting

Trial end date:
2021-05-31

Target enrollment:

Participant gender:

Summary

To evaluate the safety, tolerability, pharmacokinetics and antitumor activity of YYB101 with Irinotecan, patients who are metastatic or recurrent Colorectal Cancer Patients.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

National OncoVenture

Collaborator:

Yooyoung Pharmaceutical Co., Ltd.